Clinical Trials in China / NCT07146100
Recruiting
Observational
Long-term Follow-up Study to Evaluate Participants With Chronic Hepatitis B (CHB) Previously Treated With AHB-137 Injection
NCT07146100 · tracked via the Priya Life Science China tracker
Condition(s) studied
Chronic Hepatitis B
Study summary
This study is a prospective, open-label, multicenter long-term follow-up study to evaluate the durability of virologic response in subjects with chronic hepatitis B previously treated with AHB-137 injection.
Eligibility
Inclusion Criteria:
* Capable of giving informed consent.
* Participants who have previously received at least one dose of AHB-137 and achieved the complete of partial response in the parent study without rescue medication and who maintained response until the End of Study (EoS) visit in their parent study.
Exclusion Criteria:
* Participants who have/or are currently participating in another interventional clinical study since completing their treatment with AHB-137.
* Suspected for cancer at screening or any condition required hospitalization during this study , or any condition which, in the opinion of the investigator or Medical Monitor, contraindicates their participation in this study.
Primary outcome measure(s)
- Percentage of participants maintained complete response(defined as HBsAg < 0.05IU/mL and HBV DNA < lower limit of quantification). — Up to 80 weeks
Trial sites (37)
| Facility | City | Region | Status |
|---|---|---|---|
| AusperBio Investigational Site | Hefei | Anhui | Not Yet Recruiting |
| AusperBio Investigational Site | Beijing | Beijing Municipality | Not Yet Recruiting |
| AusperBio Investigational Site | Chongqing | Chongqing Municipality | Recruiting |
| AusperBio Investigational Site | Chongqing | Chongqing Municipality | Not Yet Recruiting |
| AusperBio Investigational Site | Fuzhou | Fujian | Recruiting |
| AusperBio Investigational Site | Xiamen | Fujian | Not Yet Recruiting |
| AusperBio Investigational Site | Lanzhou | Gansu | Not Yet Recruiting |
| AusperBio Investigational Site | Foshan | Guangdong | Not Yet Recruiting |
| AusperBio Investigational Site | Guangzhou | Guangdong | Recruiting |
| AusperBio Investigational Site | Guangzhou | Guangdong | Recruiting |
| AusperBio Investigational Site | Guangzhou | Guangdong | Not Yet Recruiting |
| AusperBio Investigational Site | Guangzhou | Guangdong | Not Yet Recruiting |
| AusperBio Investigational Site | Shenzhen | Guangdong | Not Yet Recruiting |
| AusperBio Investigational Site | Shenzhen | Guangdong | Not Yet Recruiting |
| AusperBio Investigational Site | Liuzhou | Guangxi | Not Yet Recruiting |
| AusperBio Investigational Site | Nanning | Guangxi | Not Yet Recruiting |
| AusperBio Investigational Site | Zunyi | Guizhou | Not Yet Recruiting |
| AusperBio Investigational Site | Haikou | Hainan | Not Yet Recruiting |
| AusperBio Investigational Site | Zhengzhou | Henan | Not Yet Recruiting |
| AusperBio Investigational Site | Wuhan | Hubei | Not Yet Recruiting |
| AusperBio Investigational Site | Changsha | Hunan | Not Yet Recruiting |
| AusperBio Investigational Site | Changsha | Hunan | Not Yet Recruiting |
| AusperBio Investigational Site | Changhou | Jiangsu | Recruiting |
| AusperBio Investigational Site | Nanjing | Jiangsu | Not Yet Recruiting |
| AusperBio Investigational Site | Zhenjiang | Jiangsu | Recruiting |
| AusperBio Investigational Site | Nanchang | Jiangxi | Not Yet Recruiting |
| AusperBio Investigational Site | Changchun | Jilin | Recruiting |
| AusperBio Investigational Site | Shenyang | Liaoning | Not Yet Recruiting |
| AusperBio Investigational Site | Shanghai | Shanghai Municipality | Not Yet Recruiting |
| AusperBio Investigational Site | Taiyuan | Shanxi | Not Yet Recruiting |
| AusperBio Investigational Site | Xi’an | Shanxi | Not Yet Recruiting |
| AusperBio Investigational Site | Chengdu | Sichuan | Not Yet Recruiting |
| AusperBio Investigational Site | Chengdu | Sichuan | Not Yet Recruiting |
| AusperBio Investigational Site | Kunming | Yunnan | Not Yet Recruiting |
| AusperBio Investigational Site | Hangzhou | Zhejiang | Recruiting |
| AusperBio Investigational Site | Hangzhou | Zhejiang | Not Yet Recruiting |
| AusperBio Investigational Site | Hangzhou | Zhejiang | Not Yet Recruiting |
More Ausper Biopharma Co., Ltd. trials in China
Other trials for the same condition
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
Active, not recruiting
Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection
Active, not recruiting
Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB)
Active, not recruiting
A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B.
Enrolling by invitation
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07146100 on ClinicalTrials.gov ↗ ← All trials in China